Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 18/20 | 0.72 |
| ▸ | ELOC | Q15369 | 9/20 | 0.72 |
| ▸ | ELOB | Q15370 | 9/20 | 0.72 |
| ▸ | STAT3 | P40763 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | BCR | P11274 | 1/20 | 0.54 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25781146 | 0.99 | VHL (0.74) | VHLELOCELOBSTAT3ABL1 | |
| SCHEMBL23772458 | 0.99 | VHL (0.74) | VHLELOCELOBSTAT3ABL1 | |
| SCHEMBL25855799 | 0.97 | VHL (0.76) | VHLELOCELOBSTAT3ABL1 | |
| SCHEMBL25856310 | 0.96 | VHL (0.78) | VHLELOCELOBSTAT3ABL1 | |
| SCHEMBL22511940 | 0.95 | VHL (0.73) | VHLELOCELOBSTAT3ABL1 | |
| SCHEMBL25856107 | 0.94 | VHL (0.75) | VHLELOCELOBSTAT3 | |
| SCHEMBL24357872 | 0.94 | VHL (0.75) | VHLELOCELOBSTAT3 | |
| SCHEMBL23431295 | 0.94 | VHL (0.75) | VHLELOCELOBSTAT3 | |
| SCHEMBL23431473 | 0.94 | VHL (0.74) | VHLELOCELOBSTAT3 | |
| SCHEMBL25856131 | 0.94 | VHL (0.74) | VHLELOCELOBSTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242506-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | GENENTECHT, INC. (US) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242506-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | TEAD1, TEAD2, TEAD4 | VHL 16/4885ELOC 2242/4885ELOB 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.